It is worth mentioning that the COVID-19 patients included in the study were given three treatments according to the actual guidance—remdesivir (i.v.): once per day, first dose 200 mg, next 4 days 100 mg; tocilizumab (i.v.): single dose of 400/600/800 mg (depending on body weight), repeated after 8–24 h if needed; convalescent plasma (i.v.): single dose of 400 mL of AB0-compatible convalescent plasma, but these treatments did not appear to significantly impact the PD-1/PD-L1 axis. This evidence concerns the gene CD274 and COVID-19.